|
US7407943B2
(en)
*
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
|
US7511131B2
(en)
|
2002-11-13 |
2009-03-31 |
Genzyme Corporation |
Antisense modulation of apolipoprotein B expression
|
|
US20060009410A1
(en)
*
|
2002-11-13 |
2006-01-12 |
Crooke Rosanne M |
Effects of apolipoprotein B inhibition on gene expression profiles in animals
|
|
JP2005244488A
(ja)
|
2004-02-25 |
2005-09-08 |
Matsushita Electric Ind Co Ltd |
複合機
|
|
US20050287558A1
(en)
|
2004-05-05 |
2005-12-29 |
Crooke Rosanne M |
SNPs of apolipoprotein B and modulation of their expression
|
|
US20070087987A1
(en)
*
|
2005-09-19 |
2007-04-19 |
Monia Brett P |
Modulation of glucagon receptor expression
|
|
US8288354B2
(en)
|
2005-12-28 |
2012-10-16 |
The Scripps Research Institute |
Natural antisense and non-coding RNA transcripts as drug targets
|
|
US7764650B2
(en)
|
2006-03-02 |
2010-07-27 |
Intel Corporation |
Mobile station and method for fast roaming with integrity protection and source authentication using a common protocol
|
|
EP3431602A1
(en)
|
2006-04-03 |
2019-01-23 |
Roche Innovation Center Copenhagen A/S |
Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
|
|
WO2007112754A2
(en)
|
2006-04-03 |
2007-10-11 |
Santaris Pharma A/S |
Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides
|
|
JP5825754B2
(ja)
*
|
2006-05-05 |
2015-12-02 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
Ａｐｏｂの発現を調節するための化合物および方法
|
|
EP2052079A2
(en)
*
|
2006-07-17 |
2009-04-29 |
Sirna Therapeutics Inc. |
Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina)
|
|
CA2667055C
(en)
*
|
2006-10-18 |
2017-05-09 |
Isis Pharmaceuticals, Inc. |
Antisense compounds
|
|
US8093222B2
(en)
|
2006-11-27 |
2012-01-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
|
KR20090103894A
(ko)
|
2006-11-27 |
2009-10-01 |
아이시스 파마수티컬즈 인코포레이티드 |
고콜레스테롤혈증을 치료하는 방법
|
|
US8470791B2
(en)
*
|
2007-03-22 |
2013-06-25 |
Santaris Pharma A/S |
RNA antagonist compounds for the inhibition of Apo-B100 expression
|
|
CN103480002A
(zh)
|
2007-03-24 |
2014-01-01 |
基酶有限公司 |
施用与人载脂蛋白 b互补的反义寡核苷酸
|
|
KR20100024399A
(ko)
|
2007-05-01 |
2010-03-05 |
엔즌 파마슈티칼스, 인코포레이티드 |
베타-카테닌의 조절용 ｒｎａ 길항제 화합물
|
|
KR20100024410A
(ko)
|
2007-05-11 |
2010-03-05 |
엔즌 파마슈티칼스, 인코포레이티드 |
Ｈｅｒ３ 조절용 ｒｎａ 길항제 화합물
|
|
ATE538127T1
(de)
†
|
2007-07-05 |
2012-01-15 |
Isis Pharmaceuticals Inc |
6-disubstituierte bicyclische nukleinsäureanaloga
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
WO2009046426A2
(en)
|
2007-10-04 |
2009-04-09 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for improving cellular uptake of oligomeric compounds
|
|
ES2406686T3
(es)
|
2007-10-04 |
2013-06-07 |
Santaris Pharma A/S |
Micromirs
|
|
US8450290B2
(en)
|
2007-11-26 |
2013-05-28 |
Enzon Pharmaceuticals, Inc. |
Methods for treating androgen receptor dependent disorders including cancers
|
|
CN101932709B
(zh)
|
2007-11-26 |
2014-09-10 |
桑塔里斯制药公司 |
靶向雄激素受体的lna拮抗剂
|
|
US20100323967A1
(en)
*
|
2007-12-07 |
2010-12-23 |
Santaris Pharma A/S |
RNA Antagonist Compounds for the Modulation of MCL-1
|
|
CN102016036B
(zh)
|
2008-02-11 |
2015-04-08 |
阿克赛医药公司 |
经修饰的RNAi多核苷酸及其用途
|
|
EP2268811A1
(en)
|
2008-03-07 |
2011-01-05 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of microrna related diseases
|
|
EP2282744B1
(en)
|
2008-03-21 |
2018-01-17 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising tricyclic nucleosides and methods for their use
|
|
US8846639B2
(en)
|
2008-04-04 |
2014-09-30 |
Isis Pharmaceutical, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
|
US20110224280A1
(en)
*
|
2008-04-16 |
2011-09-15 |
Niels Fisker Nielsen |
Pharmaceutical Composition Comprising Anti PCSK9 Oligomers
|
|
WO2009143390A2
(en)
|
2008-05-22 |
2009-11-26 |
Isis Pharmaceuticals, Inc. |
Methods for modulating expression of rbp4
|
|
EP2297322A1
(en)
|
2008-06-04 |
2011-03-23 |
The Board of Regents of The University of Texas System |
Modulation of gene expression through endogenous small rna targeting of gene promoters
|
|
WO2009148605A2
(en)
*
|
2008-06-04 |
2009-12-10 |
Isis Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia
|
|
AU2009276763B2
(en)
|
2008-07-29 |
2015-07-16 |
The Board Of Regents Of The University Of Texas Sytem |
Selective inhibition of polyglutamine protein expression
|
|
ES2541442T3
(es)
|
2008-08-01 |
2015-07-20 |
Roche Innovation Center Copenhagen A/S |
Modulación mediada por microARN de factores estimulantes de colonias
|
|
CN103429270B
(zh)
|
2008-08-25 |
2016-11-23 |
埃克斯雷德制药有限公司 |
阻止结缔组织生长因子的反义核苷酸及其用途
|
|
EP2334319B1
(en)
|
2008-08-25 |
2017-12-06 |
Excaliard Pharmaceuticals, Inc. |
Method for reducing scarring during wound healing using antisense compounds directed to ctgf
|
|
CN102405286A
(zh)
|
2008-09-22 |
2012-04-04 |
阿克赛医药公司 |
减小大小的自递送RNAi化合物
|
|
MX339820B
(es)
|
2008-10-03 |
2016-06-13 |
Curna Inc |
Compuestos oligonucleottidos designados para inhibir el transcrito antisentido natrual apra apolipoproteina-a1.
|
|
EP3335715A3
(en)
*
|
2008-10-15 |
2018-08-08 |
Ionis Pharmaceuticals, Inc. |
Modulation of factor 11 expression
|
|
US8883752B2
(en)
*
|
2008-10-24 |
2014-11-11 |
Isis Pharmaceuticals, Inc. |
5′ and 2′ BIS-substituted nucleosides and oligomeric compounds prepared therefrom
|
|
CA2744987C
(en)
|
2008-12-02 |
2018-01-16 |
Chiralgen, Ltd. |
Method for the synthesis of phosphorus atom modified nucleic acids
|
|
ES2600781T3
(es)
|
2008-12-04 |
2017-02-10 |
Curna, Inc. |
Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf
|
|
CN102317458B
(zh)
|
2008-12-04 |
2018-01-02 |
库尔纳公司 |
通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗
|
|
KR101866152B1
(ko)
|
2008-12-04 |
2018-06-08 |
큐알엔에이, 인크. |
종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
|
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
|
AU2010211133A1
(en)
*
|
2009-02-03 |
2011-07-21 |
F. Hoffmann-La Roche Ag |
Compositions and methods for inhibiting expression of PTP1B genes
|
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
|
JP6066035B2
(ja)
*
|
2009-02-12 |
2017-01-25 |
クルナ・インコーポレーテッド |
グリア細胞由来神経栄養因子（ｇｄｎｆ）関連疾病の、ｇｄｎｆに対する天然アンチセンス転写物の抑制による治療
|
|
EP3009150B1
(en)
|
2009-02-12 |
2019-11-13 |
CuRNA, Inc. |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
|
WO2010107733A2
(en)
|
2009-03-16 |
2010-09-23 |
Curna, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
|
|
EP2408796B1
(en)
|
2009-03-16 |
2020-04-22 |
Ionis Pharmaceuticals, Inc. |
Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III
|
|
WO2010107740A2
(en)
|
2009-03-17 |
2010-09-23 |
Curna, Inc. |
Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
|
|
EP2421970B1
(en)
|
2009-04-24 |
2016-09-07 |
Roche Innovation Center Copenhagen A/S |
Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
|
|
US8815586B2
(en)
|
2009-04-24 |
2014-08-26 |
The Board Of Regents Of The University Of Texas System |
Modulation of gene expression using oligomers that target gene regions downstream of 3′ untranslated regions
|
|
CN103223177B
(zh)
|
2009-05-06 |
2016-08-10 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
|
EP2427552B1
(en)
|
2009-05-06 |
2016-11-16 |
CuRNA, Inc. |
Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
|
|
EP2427554B1
(en)
|
2009-05-08 |
2016-11-16 |
CuRNA, Inc. |
Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
|
|
JP2012526533A
(ja)
*
|
2009-05-15 |
2012-11-01 |
エフ．ホフマン−ラ ロシュ アーゲー |
グルココルチコイドレセプター（ｇｃｒ）遺伝子の発現を阻害するための組成物及び方法
|
|
EP2432881B1
(en)
|
2009-05-18 |
2017-11-15 |
CuRNA, Inc. |
Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
|
|
US8895527B2
(en)
|
2009-05-22 |
2014-11-25 |
Curna, Inc. |
Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3
|
|
JP5960049B2
(ja)
|
2009-05-28 |
2016-08-02 |
クルナ・インコーポレーテッド |
抗ウイルス遺伝子に対する天然アンチセンス転写物の抑制による抗ウイルス遺伝子関連疾患の治療
|
|
US8951981B2
(en)
|
2009-06-16 |
2015-02-10 |
Curna, Inc. |
Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1
|
|
CN102695797B
(zh)
|
2009-06-16 |
2018-05-25 |
库尔纳公司 |
通过抑制针对胶原基因的天然反义转录物来治疗胶原基因相关的疾病
|
|
CA2765889A1
(en)
|
2009-06-24 |
2010-12-29 |
Opko Curna, Llc |
Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
|
|
CA2765815A1
(en)
|
2009-06-26 |
2010-12-29 |
Opko Curna, Llc |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
|
CA2767253A1
(en)
|
2009-07-06 |
2011-01-13 |
Ontorii, Inc. |
Novel nucleic acid prodrugs and methods of use thereof
|
|
US8563528B2
(en)
|
2009-07-21 |
2013-10-22 |
Santaris Pharma A/S |
Antisense oligomers targeting PCSK9
|
|
KR101801407B1
(ko)
|
2009-07-24 |
2017-11-24 |
큐알엔에이, 인크. |
시르투인 (ｓｉｒｔ)에 대한 천연 안티센스 전사체의 억제에 의한 시르투인 관련된 질환의 치료
|
|
JP6128848B2
(ja)
|
2009-08-05 |
2017-05-17 |
クルナ・インコーポレーテッド |
インスリン遺伝子（ｉｎｓ）に対する天然アンチセンス転写物の抑制によるインスリン遺伝子（ｉｎｓ）関連疾患の治療
|
|
CA2770104C
(en)
|
2009-08-11 |
2019-03-19 |
Opko Curna, Llc |
Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
|
|
WO2011022606A2
(en)
|
2009-08-21 |
2011-02-24 |
Curna, Inc. |
Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
|
|
CN102482671B
(zh)
|
2009-08-25 |
2017-12-01 |
库尔纳公司 |
通过抑制‘含有iq模体的gtp酶激活蛋白’(iqgap)的天然反义转录物而治疗iqgap相关疾病
|
|
US20120295952A1
(en)
|
2009-09-25 |
2012-11-22 |
Curna, Inc. |
Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
|
|
EP2480667A4
(en)
*
|
2009-09-25 |
2013-07-03 |
Isis Pharmaceuticals Inc |
MODULATION OF TTC39 EXPRESSION FOR HDL INCREASE
|
|
CA2780741C
(en)
|
2009-10-12 |
2023-04-04 |
Smith Holdings, Llc |
Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
|
|
CN105861698A
(zh)
*
|
2009-10-12 |
2016-08-17 |
医学免疫有限责任公司 |
Ir-a 和 ir-b 的定量用于肿瘤分类
|
|
WO2011053994A1
(en)
|
2009-11-02 |
2011-05-05 |
Alnylam Pharmaceuticals, Inc. |
Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
|
|
WO2011054811A1
(en)
|
2009-11-03 |
2011-05-12 |
Santaris Pharma A/S |
Rna antagonists targeting hsp27 combination therapy
|
|
RU2639550C2
(ru)
|
2009-12-16 |
2017-12-21 |
Курна, Инк. |
Лечение заболеваний, связанных с сайт-1 мембраносвязанной пептидазой транскрипционных факторов (mbtps1), путем ингибирования природного антисмыслового транскрипта к mbtps1
|
|
CN102781480B
(zh)
|
2009-12-23 |
2018-07-27 |
库尔纳公司 |
通过抑制解偶联蛋白2(ucp2)的天然反义转录物而治疗ucp2相关疾病
|
|
US8940708B2
(en)
|
2009-12-23 |
2015-01-27 |
Curna, Inc. |
Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
|
|
JP5982288B2
(ja)
|
2009-12-29 |
2016-08-31 |
カッパーアールエヌエー，インコーポレイテッド |
腫瘍タンパク質６３（ｐ６３）に対する天然アンチセンス転写物の阻害による腫瘍タンパク質６３関連疾患の治療
|
|
EP2519633B1
(en)
|
2009-12-29 |
2017-10-25 |
CuRNA, Inc. |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
|
EP2519632B1
(en)
|
2009-12-31 |
2018-04-11 |
CuRNA, Inc. |
Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
|
|
RU2611187C2
(ru)
|
2010-01-04 |
2017-02-21 |
Курна, Инк. |
Лечение заболеваний, связанных с интерферон-регуляторным фактором 8 (irf8), путем ингибирования природного антисмыслового транскрипта к irf8
|
|
EP2521785B1
(en)
|
2010-01-06 |
2022-03-09 |
CuRNA, Inc. |
Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases
|
|
EP2521556B1
(en)
|
2010-01-08 |
2018-05-30 |
Ionis Pharmaceuticals, Inc. |
Modulation of angiopoietin-like 3 expression
|
|
KR101854926B1
(ko)
|
2010-01-11 |
2018-05-04 |
큐알엔에이, 인크. |
성 호르몬 결합 글로불린 (ｓｈｂｇ)에 대한 자연 안티센스 전사체의 저해에 의한 성 호르몬 결합 글로불린 (ｓｈｂｇ) 관련된 질환의 치료
|
|
WO2011088148A1
(en)
*
|
2010-01-12 |
2011-07-21 |
Isis Pharmaceuticals, Inc. |
Modulation of transforming growth factor-beta 1 expression
|
|
CA2786568A1
(en)
|
2010-01-25 |
2011-07-28 |
Curna, Inc. |
Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
|
|
US9574191B2
(en)
|
2010-02-03 |
2017-02-21 |
The Board Of Regents Of The University Of Texas System |
Selective inhibition of polyglutamine protein expression
|
|
US9006198B2
(en)
*
|
2010-02-08 |
2015-04-14 |
Isis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
|
EP3561060A1
(en)
|
2010-02-08 |
2019-10-30 |
Ionis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
|
JP5976548B2
(ja)
|
2010-02-22 |
2016-08-23 |
カッパーアールエヌエー，インコーポレイテッド |
Ｐｙｃｒ１に対する天然アンチセンス転写物の阻害によるピロリン−５−カルボン酸レダクターゼ１（ｐｙｃｒ１）関連疾患の治療
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
EP2545173A2
(en)
*
|
2010-03-12 |
2013-01-16 |
Sarepta Therapeutics, Inc. |
Antisense modulation of nuclear hormone receptors
|
|
US9340786B2
(en)
|
2010-03-24 |
2016-05-17 |
Rxi Pharmaceuticals Corporation |
RNA interference in dermal and fibrotic indications
|
|
CA2795145C
(en)
|
2010-04-02 |
2019-01-22 |
Curna, Inc. |
Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
|
|
CN102858979B
(zh)
|
2010-04-09 |
2018-01-26 |
库尔纳公司 |
通过抑制成纤维细胞生长因子21(fgf21)的天然反义转录物而治疗fgf21相关疾病
|
|
KR20130101442A
(ko)
*
|
2010-05-03 |
2013-09-13 |
큐알엔에이, 인크. |
시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
|
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
|
|
DK2576783T3
(en)
|
2010-05-26 |
2018-03-12 |
Curna Inc |
TREATMENT OF ATONAL HOMOLOGY 1- (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS AT ATOH1
|
|
EP2576784B1
(en)
|
2010-05-26 |
2017-11-15 |
CuRNA, Inc. |
Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
|
|
CA2801342A1
(en)
|
2010-06-04 |
2011-12-08 |
Eric N. Olson |
Regulation of metabolism by mir-378
|
|
WO2011156763A1
(en)
*
|
2010-06-11 |
2011-12-15 |
Hitachi Chemical Co., Ltd. |
Methods for characterizing kidney function
|
|
WO2011156734A2
(en)
|
2010-06-11 |
2011-12-15 |
Hitachi Chemical Co., Ltd. |
Method of characterizing vascular diseases
|
|
US9518259B2
(en)
|
2010-06-15 |
2016-12-13 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating interaction between proteins and target nucleic acids
|
|
US8933024B2
(en)
|
2010-06-18 |
2015-01-13 |
Sanofi |
Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
JP6023705B2
(ja)
|
2010-06-23 |
2016-11-09 |
カッパーアールエヌエー，インコーポレイテッド |
ナトリウムチャネル、電位依存性、αサブユニット（ＳＣＮＡ）に対する天然アンチセンス転写物の阻害によるＳＣＮＡ関連疾患の治療
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
EP2593547B1
(en)
|
2010-07-14 |
2017-11-15 |
CuRNA, Inc. |
Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
|
|
JP5875006B2
(ja)
*
|
2010-08-31 |
2016-03-02 |
国立大学法人大阪大学 |
オリゴヌクレオチド、およびオリゴヌクレオチドを有効成分として含有する脂質異常症治療剤
|
|
WO2012034942A1
(en)
|
2010-09-13 |
2012-03-22 |
Santaris Pharma A/S |
Compounds for the modulation of aurora kinase b expression
|
|
WO2012039448A1
(ja)
|
2010-09-24 |
2012-03-29 |
株式会社キラルジェン |
不斉補助基
|
|
KR101886457B1
(ko)
*
|
2010-10-06 |
2018-08-07 |
큐알엔에이, 인크. |
시알리다아제 4 (neu4)에 대한 자연 안티센스 전사체의 저해에 의한 neu4 관련된 질환의 치료
|
|
CN103180445B
(zh)
|
2010-10-22 |
2018-02-16 |
库尔纳公司 |
通过抑制α‑L‑艾杜糖醛酸酶(IDUA)的天然反义转录物而治疗IDUA相关疾病
|
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
|
CA2817256A1
(en)
|
2010-11-12 |
2012-05-18 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
|
US10000752B2
(en)
|
2010-11-18 |
2018-06-19 |
Curna, Inc. |
Antagonat compositions and methods of use
|
|
WO2012066093A1
(en)
|
2010-11-19 |
2012-05-24 |
Santaris Pharma A/S |
Compounds for the modulation of pdz-binding kinase (pbk) expression
|
|
WO2012066092A1
(en)
|
2010-11-19 |
2012-05-24 |
Santaris Pharma A/S |
Compounds for the modulation of aurora kinase a expression
|
|
JO3756B1
(ar)
|
2010-11-23 |
2021-01-31 |
Regeneron Pharma |
اجسام مضادة بشرية لمستقبلات الجلوكاجون
|
|
US8771696B2
(en)
|
2010-11-23 |
2014-07-08 |
Regeneron Pharmaceuticals, Inc. |
Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
|
|
CA2818824A1
(en)
|
2010-11-23 |
2012-05-31 |
Joseph Collard |
Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
|
|
CN110711248A
(zh)
|
2011-01-28 |
2020-01-21 |
赛诺菲生物技术公司 |
包含针对pcsk9的人抗体的药物组合物
|
|
US9173894B2
(en)
|
2011-02-02 |
2015-11-03 |
Excaliard Pharamaceuticals, Inc. |
Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)
|
|
EP3467109A1
(en)
*
|
2011-02-08 |
2019-04-10 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
WO2012110457A2
(en)
|
2011-02-14 |
2012-08-23 |
Santaris Pharma A/S |
Compounds for the modulation of osteopontin expression
|
|
AU2012242642A1
(en)
|
2011-04-13 |
2013-05-02 |
Ionis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
|
WO2012143427A1
(en)
|
2011-04-19 |
2012-10-26 |
Santaris Pharma A/S |
Anti polyomavirus compounds
|
|
JP2014519806A
(ja)
|
2011-04-20 |
2014-08-21 |
スミス ホールディングス，エルエルシー |
細胞内で自己会合し、ＲＮＡｉ活性を産生する組成物を使用した遺伝子発現を調節するための方法および成分
|
|
RU2620980C2
(ru)
|
2011-06-09 |
2017-05-30 |
Курна, Инк. |
Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn
|
|
JP5823031B2
(ja)
|
2011-06-10 |
2015-11-25 |
日立化成株式会社 |
小胞捕捉デバイスおよびそれを用いるための方法
|
|
WO2013012758A1
(en)
|
2011-07-19 |
2013-01-24 |
Ontorii, Inc. |
Methods for the synthesis of functionalized nucleic acids
|
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
US20140303235A1
(en)
|
2011-08-11 |
2014-10-09 |
Isis Pharmaceuticals, Inc. |
Linkage modified gapped oligomeric compounds and uses thereof
|
|
JP6125505B2
(ja)
|
2011-09-06 |
2017-05-10 |
カッパーアールエヌエー，インコーポレイテッド |
小分子による電位開口型ナトリウムチャネル・アルファサブユニット関連疾患の治療
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
WO2013040429A1
(en)
|
2011-09-14 |
2013-03-21 |
Rana Therapeutics Inc. |
Multimeric oligonucleotide compounds
|
|
ES2992345T3
(es)
|
2011-09-16 |
2024-12-11 |
Regeneron Pharma |
Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9)
|
|
DK2758533T3
(en)
*
|
2011-09-20 |
2018-05-28 |
Ionis Pharmaceuticals Inc |
ANTISENCE MODULATION OF GCGR EXPRESSION
|
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
HK1201555A1
(en)
|
2011-10-25 |
2015-09-04 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of gccr expression
|
|
EP2791335B1
(en)
|
2011-12-16 |
2018-11-14 |
National University Corporation Tokyo Medical and Dental University |
Chimeric double-stranded nucleic acid
|
|
TR201815503T4
(tr)
|
2012-03-15 |
2018-11-21 |
Curna Inc |
Beyin kaynaklı nörotrofik faktör (bknf) ile ilişkili hastalıkların doğal antisens transkriptinin bknf'ye inhibisyonu ile muamelesi.
|
|
AU2013203395A1
(en)
|
2012-03-30 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating TAU expression for reducing seizure and modifying a neurodegenerative syndrome
|
|
EP3336189A1
(en)
|
2012-04-20 |
2018-06-20 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
US9255154B2
(en)
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
|
EP2850187A4
(en)
*
|
2012-05-16 |
2016-01-20 |
Rana Therapeutics Inc |
COMPOSITIONS AND METHODS FOR MODULATING PTEN EXPRESSION
|
|
JP2015518710A
(ja)
|
2012-05-16 |
2015-07-06 |
ラナ セラピューティクス インコーポレイテッド |
ヘモグロビン遺伝子ファミリー発現を調節するための組成物及び方法
|
|
US20150133362A1
(en)
*
|
2012-05-16 |
2015-05-14 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating gene expression
|
|
EA201492123A1
(ru)
|
2012-05-16 |
2015-10-30 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии семейства генов smn
|
|
AU2013262699A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating ATP2A2 expression
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
EA201492122A1
(ru)
|
2012-05-16 |
2015-10-30 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии utrn
|
|
US20150152410A1
(en)
|
2012-05-16 |
2015-06-04 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating mecp2 expression
|
|
WO2013173789A2
(en)
|
2012-05-17 |
2013-11-21 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions
|
|
CN108359668A
(zh)
*
|
2012-05-24 |
2018-08-03 |
Ionis制药公司 |
用于调节载脂蛋白(a)表达的方法和组合物
|
|
US9663784B2
(en)
|
2012-05-26 |
2017-05-30 |
Bonac Corporation |
Single-stranded nucleic acid molecule for regulating expression of gene having delivering function
|
|
KR102712879B1
(ko)
|
2012-07-13 |
2024-10-04 |
웨이브 라이프 사이언시스 리미티드 |
키랄 제어
|
|
CN104684923B
(zh)
|
2012-07-13 |
2018-09-28 |
株式会社新日本科学 |
手性核酸佐剂
|
|
JP6268157B2
(ja)
|
2012-07-13 |
2018-01-24 |
株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ |
不斉補助基
|
|
WO2014043544A1
(en)
|
2012-09-14 |
2014-03-20 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotide compounds
|
|
US9993522B2
(en)
|
2012-09-18 |
2018-06-12 |
Uti Limited Partnership |
Treatment of pain by inhibition of USP5 de-ubiquitinase
|
|
US9695418B2
(en)
|
2012-10-11 |
2017-07-04 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and uses thereof
|
|
EP4144845B1
(en)
|
2012-10-12 |
2024-04-24 |
Ionis Pharmaceuticals, Inc. |
Antisense compounds and uses thereof
|
|
WO2014062691A2
(en)
|
2012-10-15 |
2014-04-24 |
Isis Pharmaceuticals, Inc. |
Compositions for modulating c9orf72 expression
|
|
EP2906697A4
(en)
|
2012-10-15 |
2016-06-22 |
Ionis Pharmaceuticals Inc |
METHOD FOR MONITORING THE C9ORF72 EXPRESSION
|
|
US20150291958A1
(en)
|
2012-11-15 |
2015-10-15 |
Roche Innovation Center Copenhagen A/S |
Anti apob antisense conjugate compounds
|
|
RU2015120645A
(ru)
|
2012-11-26 |
2017-01-10 |
Рош Инновейшен Сентер Копенгаген А/С |
Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 3 типа (fgfr3)
|
|
US20150368642A1
(en)
|
2013-01-30 |
2015-12-24 |
Hoffmann-La Roche Inc. |
Lna oligonucleotide carbohydrate conjugates
|
|
KR102190852B1
(ko)
*
|
2013-01-31 |
2020-12-14 |
아이오니스 파마수티컬즈, 인코포레이티드 |
변형된 커플링 프로토콜을 이용하는 올리고머 화합물의 제조 방법
|
|
WO2014134179A1
(en)
|
2013-02-28 |
2014-09-04 |
The Board Of Regents Of The University Of Texas System |
Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers
|
|
US20160108395A1
(en)
*
|
2013-03-01 |
2016-04-21 |
National University Corporation Tokyo Medical And Dental University |
Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
|
|
WO2014153236A1
(en)
|
2013-03-14 |
2014-09-25 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating tau expression
|
|
CA2906198C
(en)
|
2013-03-14 |
2022-11-29 |
Andes Biotechnologies S.A. |
Antisense oligonucleotides for treatment of cancer stem cells
|
|
CA2902571A1
(en)
|
2013-03-15 |
2014-09-18 |
MiRagen Therapeutics, Inc. |
Bridged bicyclic nucleosides
|
|
CA2909442A1
(en)
|
2013-04-17 |
2014-10-23 |
Pfizer Inc. |
N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
|
|
US9127276B2
(en)
|
2013-05-01 |
2015-09-08 |
Isis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
JP6297676B2
(ja)
|
2013-05-06 |
2018-03-20 |
日立化成株式会社 |
標的分子を捕捉するためのデバイス及び方法
|
|
MX363846B
(es)
|
2013-05-24 |
2019-04-05 |
Roche Innovation Ct Copenhagen As |
Moduladores de oligonucleotido de linfoma linfocitico cronico/linfoma de celulas b 11a (bcl11a) y sus usos.
|
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
|
AU2014272526A1
(en)
|
2013-05-30 |
2015-12-10 |
National University Corporation Tokyo Medical And Dental University |
Double-stranded agents for delivering therapeutic oligonucleotides
|
|
AU2014274844B2
(en)
|
2013-06-07 |
2019-11-28 |
Regeneron Pharmaceuticals, Inc. |
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
|
|
CN105324119A
(zh)
|
2013-06-16 |
2016-02-10 |
国立大学法人东京医科齿科大学 |
具有外显子跳跃效应的双链反义核酸
|
|
AU2014300981B2
(en)
|
2013-06-27 |
2017-08-10 |
Roche Innovation Center Copenhagen A/S |
Antisense oligomers and conjugates targeting PCSK9
|
|
TWI702046B
(zh)
|
2013-07-19 |
2020-08-21 |
美商Ionis製藥公司 |
用於調節τ蛋白表現之組合物
|
|
WO2015023941A1
(en)
|
2013-08-16 |
2015-02-19 |
Rana Therapeutics, Inc. |
Oligonucleotides targeting euchromatin regions of genes
|
|
EP3055414A4
(en)
|
2013-10-11 |
2017-07-19 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating c9orf72 expression
|
|
EP3068803B1
(en)
|
2013-11-12 |
2021-01-20 |
Sanofi Biotechnology |
Dosing regimens for use with pcsk9 inhibitors
|
|
KR102298476B1
(ko)
|
2013-12-24 |
2021-09-03 |
아이오니스 파마수티컬즈, 인코포레이티드 |
안지오포이에틴-유사 3 발현의 조절
|
|
CN105899663B
(zh)
|
2013-12-26 |
2019-07-26 |
学校法人东京医科大学 |
用于基因表达控制的人工模拟miRNA及其用途
|
|
CN106068324B
(zh)
|
2013-12-27 |
2020-12-29 |
株式会社博纳克 |
控制基因表达的人工匹配型miRNA及其用途
|
|
JPWO2015108048A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
|
US10144933B2
(en)
|
2014-01-15 |
2018-12-04 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
|
|
JPWO2015108046A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
|
|
EP4137572A1
(en)
|
2014-01-16 |
2023-02-22 |
Wave Life Sciences Ltd. |
Chiral design
|
|
PH12016502062B1
(en)
*
|
2014-05-01 |
2023-01-27 |
Ionis Pharmaceuticals Inc |
Compositions and methods for modulating complement factor b expression
|
|
CN106255755B
(zh)
|
2014-05-01 |
2020-07-24 |
Ionis制药公司 |
用于调节血管生成素样蛋白3表达的组合物和方法
|
|
CN110903337A
(zh)
|
2014-05-01 |
2020-03-24 |
Ionis制药公司 |
用于调节生长激素受体表达的组合物和方法
|
|
GB201408623D0
(en)
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
|
WO2015179693A1
(en)
|
2014-05-22 |
2015-11-26 |
Isis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
|
RU2735521C2
(ru)
|
2014-07-16 |
2020-11-03 |
Санофи Байотекнолоджи |
Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh)
|
|
KR20170055474A
(ko)
*
|
2014-07-31 |
2017-05-19 |
아카데미아 시니카 |
길항 pd-1 압타머 및 암 요법 관련 적용에서의 그의 적용
|
|
WO2016024205A1
(en)
|
2014-08-15 |
2016-02-18 |
Pfizer Inc. |
Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
|
|
US11198874B2
(en)
*
|
2014-08-20 |
2021-12-14 |
Lifesplice Pharma Llc |
SCN8A splice modulating oligonucleotides and methods of use thereof
|
|
EP3191591A1
(en)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
|
CA2960763A1
(en)
|
2014-09-16 |
2016-03-24 |
Regeneron Pharmaceuticals, Inc. |
Anti-glucagon antibodies and uses thereof
|
|
CA2963288A1
(en)
|
2014-10-03 |
2016-04-07 |
Cold Spring Harbor Laboratory |
Targeted augmentation of nuclear gene output
|
|
SG11201702877TA
(en)
|
2014-10-10 |
2017-05-30 |
Hoffmann La Roche |
Galnac phosphoramidites, nucleic acid conjugates thereof and their use
|
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
|
EP3904519A1
(en)
|
2014-10-30 |
2021-11-03 |
Genzyme Corporation |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
|
CA2966044A1
(en)
|
2014-10-30 |
2016-05-06 |
The General Hospital Corporation |
Methods for modulating atrx-dependent gene repression
|
|
US10266895B2
(en)
|
2014-11-05 |
2019-04-23 |
Hitachi Chemical Company Ltd. |
Exosomes and microvesicles in intestinal luminal fluids and stool and use of same for the assessment of inflammatory bowel disease
|
|
EP3218521B1
(en)
|
2014-11-12 |
2019-12-25 |
Hitachi Chemical Co., Ltd. |
Method for diagnosing organ injury
|
|
RU2716422C2
(ru)
|
2014-11-14 |
2020-03-11 |
Вояджер Терапьютикс, Инк. |
Композиции и способы лечения бокового амиотрофического склероза (als)
|
|
EP3234131B1
(en)
|
2014-12-16 |
2020-04-22 |
Roche Innovation Center Copenhagen A/S |
Chiral toxicity screening method
|
|
BR112017013664A2
(pt)
|
2014-12-27 |
2018-03-13 |
Bonac Corporation |
mirna de tipo natural, composição, métodos para inibir expressão de um gene alvo e para tratar uma doença, e, ácido nucleico de fita simples.
|
|
US10799523B2
(en)
|
2015-02-04 |
2020-10-13 |
F. Hoffmann-La Roche Ag |
Tau antisense oligomers and uses thereof
|
|
EP3254104B1
(en)
|
2015-02-04 |
2021-08-25 |
Bristol-Myers Squibb Company |
Methods of selecting therapeutic molecules
|
|
EP3256591A4
(en)
|
2015-02-13 |
2018-08-08 |
Translate Bio Ma, Inc. |
Hybrid oligonucleotides and uses thereof
|
|
EP3271460A4
(en)
|
2015-03-17 |
2019-03-13 |
The General Hospital Corporation |
RNA INTERACTOM OF POLYCOMB REPRESSIVE COMPLEX 1 (PRC1)
|
|
WO2016154629A1
(en)
|
2015-03-26 |
2016-09-29 |
Woman & Infants' Hospital Of Rhode Island |
Therapy for malignant disease
|
|
HK1244031A1
(en)
|
2015-03-27 |
2018-07-27 |
Bonac Corporation |
Single-chain nucleic acid molecule having delivery function and gene expression control ability
|
|
US10745702B2
(en)
|
2015-04-08 |
2020-08-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
|
MY181815A
(en)
|
2015-04-16 |
2021-01-08 |
Ionis Pharmaceuticals Inc |
Compositions for modulating c9orf72 expression
|
|
EP3310918B1
(en)
|
2015-06-18 |
2020-08-05 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
|
WO2016205681A1
(en)
|
2015-06-19 |
2016-12-22 |
University Of Rochester |
Septin proteins as novel biomarkers for detection and treatment of müllerian cancers
|
|
US20180312845A1
(en)
*
|
2015-07-10 |
2018-11-01 |
Ionis Pharmaceuticals, Inc. |
Modulators of diacyglycerol acyltransferase 2 (dgat2)
|
|
MA43072A
(fr)
|
2015-07-22 |
2018-05-30 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
|
US10772956B2
(en)
|
2015-08-18 |
2020-09-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
|
|
US11028443B2
(en)
|
2015-08-31 |
2021-06-08 |
Showa Denko Materials Co., Ltd. |
Molecular methods for assessing urothelial disease
|
|
JP7014721B2
(ja)
|
2015-09-18 |
2022-02-01 |
ディーエヌエーアールエックス |
インビボでの核酸発現のためのシステム及び方法
|
|
AU2016334804B2
(en)
|
2015-10-09 |
2022-03-31 |
University Of Southampton |
Modulation of gene expression and screening for deregulated protein expression
|
|
CN109563509B
(zh)
|
2015-10-19 |
2022-08-09 |
菲奥医药公司 |
靶向长非编码rna的减小尺寸的自递送核酸化合物
|
|
EP3394258B1
(en)
|
2015-10-22 |
2021-09-22 |
Roche Innovation Center Copenhagen A/S |
In vitro toxicity screening assay
|
|
US11260073B2
(en)
|
2015-11-02 |
2022-03-01 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating C90RF72
|
|
CN113952353A
(zh)
|
2015-11-06 |
2022-01-21 |
Ionis制药公司 |
调节载脂蛋白(a)表达
|
|
SI4220360T1
(sl)
|
2015-11-12 |
2024-10-30 |
F. Hoffmann - La Roche Ag |
Oligonukleotidi za indukcijo očetovske ekspresije UBE3A
|
|
WO2017106377A1
(en)
|
2015-12-14 |
2017-06-22 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
|
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
|
JP6853537B2
(ja)
|
2016-02-17 |
2021-03-31 |
国立大学法人東京工業大学 |
人工ヌクレオシド及び人工ヌクレオチド並びに人工オリゴヌクレオチド
|
|
WO2017152182A1
(en)
|
2016-03-04 |
2017-09-08 |
Rhode Island Hospital |
Targeting microrna for cancer treatment
|
|
HUE053172T2
(hu)
|
2016-03-14 |
2021-06-28 |
Hoffmann La Roche |
Oligonukleotidok a PD-L1 expresszió csökkentésére
|
|
WO2017178656A1
(en)
|
2016-04-14 |
2017-10-19 |
Roche Innovation Center Copenhagen A/S |
TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE
|
|
WO2017188898A1
(en)
|
2016-04-29 |
2017-11-02 |
Nanyang Technological University |
G-quadruplex-containing antisense oligonucleotides
|
|
CN109311925B
(zh)
*
|
2016-05-12 |
2022-06-03 |
罗氏创新中心哥本哈根有限公司 |
立体限定的氧杂氮杂磷杂环戊烷亚磷酰胺单体与核苷或寡核苷酸的增强的偶联
|
|
CN109312403B
(zh)
|
2016-06-17 |
2023-06-27 |
豪夫迈·罗氏有限公司 |
体外肾毒性筛选测定法
|
|
MA45496A
(fr)
|
2016-06-17 |
2019-04-24 |
Hoffmann La Roche |
Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
|
|
WO2017216340A1
(en)
|
2016-06-17 |
2017-12-21 |
F. Hoffmann-La Roche Ag |
In vitro nephrotoxicity screening assay
|
|
JOP20190065A1
(ar)
|
2016-09-29 |
2019-03-28 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن tau
|
|
US11260134B2
(en)
|
2016-09-29 |
2022-03-01 |
National University Corporation Tokyo Medical And Dental University |
Double-stranded nucleic acid complex having overhang
|
|
KR20190065341A
(ko)
|
2016-10-06 |
2019-06-11 |
아이오니스 파마수티컬즈, 인코포레이티드 |
올리고머 화합물들의 접합 방법
|
|
EP3529278A1
(en)
|
2016-10-20 |
2019-08-28 |
Regeneron Pharmaceuticals, Inc. |
Methods of lowering blood glucose levels
|
|
US10787665B2
(en)
*
|
2016-11-03 |
2020-09-29 |
Ohio State Innovation Foundation |
Antisense oligomers targeting HOXB-AS3 long non-coding RNA
|
|
EP3548005A4
(en)
|
2016-11-29 |
2020-06-17 |
Puretech Health LLC |
Exosomes for delivery of therapeutic agents
|
|
EP3568479A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb1 expression
|
|
WO2018130581A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rela expression
|
|
US20190345495A1
(en)
|
2017-01-13 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb2 expression
|
|
US20190345496A1
(en)
|
2017-01-13 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating relb expression
|
|
US20190338286A1
(en)
|
2017-01-13 |
2019-11-07 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rel expression
|
|
MX2019009305A
(es)
|
2017-02-06 |
2019-09-19 |
Nissan Chemical Corp |
Oligonucleotido de cadena simple.
|
|
US11261440B2
(en)
|
2017-02-21 |
2022-03-01 |
Osaka University |
Antisense oligonucleic acid
|
|
US11180756B2
(en)
|
2017-03-09 |
2021-11-23 |
Ionis Pharmaceuticals |
Morpholino modified oligomeric compounds
|
|
EP3600428A4
(en)
|
2017-03-23 |
2020-08-26 |
Dnarx |
SYSTEMS AND METHODS FOR THE EXPRESSION OF NUCLEIC ACIDS IN VIVO
|
|
JOP20190215A1
(ar)
*
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
|
EP3603648B1
(en)
|
2017-03-29 |
2025-09-17 |
Shionogi & Co., Ltd |
Complex of nucleic acid medicine and multibranched lipid
|
|
NO344051B1
(en)
*
|
2017-05-04 |
2019-08-26 |
Patogen As |
Novel virus in Fish and Method for detection
|
|
JP2020518258A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法
|
|
US11273222B2
(en)
|
2017-05-26 |
2022-03-15 |
National Cerebral And Cardiovascular Center |
Antisense nucleic acid targeting PCSK9
|
|
EP3647423A4
(en)
|
2017-06-30 |
2021-03-24 |
National University Corporation Tokyo Medical and Dental University |
STRAIGHT DOUBLE-STRANDED ANTI-MIRROR
|
|
US11555188B2
(en)
|
2017-07-26 |
2023-01-17 |
Nissan Chemical Corporation |
Single-stranded oligonucleotide
|
|
LT3673080T
(lt)
|
2017-08-25 |
2023-12-27 |
Stoke Therapeutics, Inc. |
Priešprasminiai oligomerai, skirti būklėms ir ligoms gydyti
|
|
US20200237799A1
(en)
|
2017-10-16 |
2020-07-30 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
CN119242711A
(zh)
|
2017-10-16 |
2025-01-03 |
沃雅戈治疗公司 |
肌萎缩性侧索硬化症（als）的治疗
|
|
CN118048356A
(zh)
|
2017-10-16 |
2024-05-17 |
豪夫迈·罗氏有限公司 |
减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染
|
|
JP2021505175A
(ja)
|
2017-12-11 |
2021-02-18 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Ｆｎｄｃ３ｂの発現を調節するためのオリゴヌクレオチド
|
|
CA3085211A1
(en)
|
2017-12-21 |
2019-06-27 |
F. Hoffmann-La Roche Ag |
Companion diagnostic for htra1 rna antagonists
|
|
BR112020012427A8
(pt)
|
2017-12-22 |
2024-04-02 |
Roche Innovation Ct Copenhagen As |
Oligonucleotídeos, sal farmaceuticamente aceitável, conjugado, composição farmacêutica e processo para a fabricação de um oligonucleotídeo
|
|
EP4092118A1
(en)
|
2017-12-22 |
2022-11-23 |
Roche Innovation Center Copenhagen A/S |
Novel thiophosphoramidites
|
|
MX2020005754A
(es)
|
2017-12-22 |
2020-08-20 |
Roche Innovation Ct Copenhagen As |
Oligonucleotidos gapmeros que comprenden un enlace internucleosido fosforoditioato.
|
|
CN111699258A
(zh)
|
2018-01-10 |
2020-09-22 |
哥本哈根罗氏创新中心 |
用于调控pias4表达的寡核苷酸
|
|
SG11202006142PA
(en)
|
2018-01-12 |
2020-07-29 |
Roche Innovation Ct Copenhagen As |
Alpha-synuclein antisense oligonucleotides and uses thereof
|
|
EP3737760A1
(en)
|
2018-01-12 |
2020-11-18 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating gsk3b expression
|
|
BR112020013994A2
(pt)
|
2018-01-12 |
2020-12-08 |
Bristol-Myers Squibb Company |
Oligonucleotídeos antissenso que direcionam alfa-sinucleína e seus usos
|
|
KR102839166B1
(ko)
|
2018-01-12 |
2025-07-28 |
브리스톨-마이어스 스큅 컴퍼니 |
알파-시누클레인을 표적화하는 안티센스 올리고뉴클레오티드 및 그의 용도
|
|
EP3740574A1
(en)
|
2018-01-17 |
2020-11-25 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating erc1 expression
|
|
WO2019145386A1
(en)
|
2018-01-26 |
2019-08-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating csnk1d expression
|
|
MX2020008581A
(es)
|
2018-02-21 |
2020-09-21 |
Bristol Myers Squibb Co |
Oligonucleotidos antisentido de la proteina cinasa del tipo ii delta dependiente del calcio/calmodulina (camk2d) y sus usos.
|
|
WO2019167995A1
(ja)
|
2018-02-28 |
2019-09-06 |
国立大学法人東京医科歯科大学 |
虚血病変部位特異的な遺伝子治療法
|
|
JP7394392B2
(ja)
|
2018-03-14 |
2023-12-08 |
国立大学法人 東京医科歯科大学 |
核酸複合体
|
|
EP3769769A4
(en)
|
2018-03-19 |
2022-05-04 |
National University Corporation Tokyo Medical and Dental University |
NUCLEIC ACID WITH REDUCED TOXICITY
|
|
EP3770256A4
(en)
*
|
2018-03-20 |
2021-12-22 |
Tokyo Institute of Technology |
OLIGONUCLEOTIDE ANTISENS WITH REDUCED TOXICITY
|
|
WO2019182109A1
(ja)
|
2018-03-22 |
2019-09-26 |
国立大学法人東京医科歯科大学 |
ヘテロ核酸のｂｂｂ通過脂質リガンド
|
|
AU2019242912B2
(en)
|
2018-03-28 |
2025-07-17 |
Board Of Regents, The University Of Texas System |
Identification of epigenetic alterations in DNA isolated from exosomes
|
|
MA52661A
(fr)
|
2018-04-05 |
2021-02-17 |
Centre Leon Berard |
Utilisation d'inhibiteurs de fubp1 dans le traitement d'une infection par le virus de l'hépatite b
|
|
BR112020022512A2
(pt)
|
2018-05-04 |
2021-05-04 |
Stoke Therapeutics, Inc. |
métodos e composições para tratamento de doença de armazenamento de éster de colesteril
|
|
PE20210393A1
(es)
|
2018-05-09 |
2021-03-02 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para la reduccion de la expresion de fxi
|
|
US11833168B2
(en)
*
|
2018-06-14 |
2023-12-05 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for increasing STMN2 expression
|
|
US20210254103A1
(en)
|
2018-07-02 |
2021-08-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
|
|
PE20210346A1
(es)
|
2018-07-03 |
2021-02-25 |
Hoffmann La Roche |
Oligonucleotidos para modular la expresion de tau
|
|
AU2019300324A1
(en)
|
2018-07-13 |
2021-01-21 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating RTEL1 expression
|
|
JP7182308B2
(ja)
|
2018-07-27 |
2022-12-02 |
国立大学法人大阪大学 |
老化の抑制、加齢性の疾患もしくは症状の予防、改善、もしくは治療、または寿命の延長のための組成物
|
|
JP7470097B2
(ja)
|
2018-07-31 |
2024-04-17 |
ロシュ イノベーション センター コペンハーゲン エーエス |
ホスホロトリチオアートヌクレオシド間結合を含むオリゴヌクレオチド
|
|
CA3098267A1
(en)
|
2018-07-31 |
2020-02-06 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
KR20210081324A
(ko)
|
2018-08-02 |
2021-07-01 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
AU2019362923B2
(en)
*
|
2018-10-18 |
2025-04-10 |
ProGenis Pty Ltd |
Antisense therapy for PTP1B related conditions
|
|
WO2020169696A1
(en)
|
2019-02-20 |
2020-08-27 |
Roche Innovation Center Copenhagen A/S |
Novel phosphoramidites
|
|
AU2020225687A1
(en)
|
2019-02-20 |
2021-08-19 |
Roche Innovation Center Copenhagen A/S |
Phosphonoacetate gapmer oligonucleotides
|
|
EP3981431A4
(en)
|
2019-03-14 |
2023-06-28 |
Rena Therapeutics Inc. |
Nucleic acid complex for modulating ihh expression
|
|
JP7687682B2
(ja)
|
2019-04-08 |
2025-06-03 |
国立大学法人東京科学大学 |
筋疾患治療用医薬組成物
|
|
EP4005602A4
(en)
|
2019-07-30 |
2024-06-12 |
Shionogi & Co., Ltd |
NUCLEIC ACID AGENT TARGETED AGAINST MURF1
|
|
CN114641570A
(zh)
|
2019-08-14 |
2022-06-17 |
科迪亚克生物科学公司 |
具有靶向kras的反义寡核苷酸的细胞外囊泡
|
|
WO2021030773A1
(en)
|
2019-08-14 |
2021-02-18 |
Codiak Biosciences, Inc. |
Extracellular vesicle-nlrp3 antagonist
|
|
EP4470619A3
(en)
|
2019-08-14 |
2025-04-23 |
Lonza Sales AG |
Extracellular vesicle-aso constructs targeting stat6
|
|
US20230002764A1
(en)
|
2019-08-14 |
2023-01-05 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting cebp/beta
|
|
EP4013875A1
(en)
|
2019-08-14 |
2022-06-22 |
Codiak BioSciences, Inc. |
Extracellular vesicles with stat3-antisense oligonucleotides
|
|
CN114555621B
(zh)
|
2019-08-15 |
2025-10-28 |
Ionis制药公司 |
键修饰的寡聚化合物及其用途
|
|
CN114269924A
(zh)
*
|
2019-08-23 |
2022-04-01 |
国立大学法人东海国立大学机构 |
Rna作用抑制剂及其应用
|
|
WO2021054370A1
(ja)
|
2019-09-18 |
2021-03-25 |
国立大学法人東京医科歯科大学 |
核酸複合体
|
|
US20230241089A1
(en)
|
2019-09-25 |
2023-08-03 |
Codiak Biosciences, Inc. |
Sting agonist comprising exosomes for treating neuroimmunological disorders
|
|
JPWO2021070959A1
(enExample)
|
2019-10-11 |
2021-04-15 |
|
|
|
MX2022007909A
(es)
|
2019-12-24 |
2022-07-21 |
Hoffmann La Roche |
Combinacion farmaceutica de agentes antivirales que actuan sobre hbv y/o un inmunomodulador para el tratamiento de hbv.
|
|
CN114846140A
(zh)
|
2019-12-24 |
2022-08-02 |
豪夫迈·罗氏有限公司 |
用于治疗hbv的靶向hbv的治疗性寡核苷酸和tlr7激动剂的药物组合
|
|
WO2021153747A1
(ja)
|
2020-01-31 |
2021-08-05 |
株式会社三和化学研究所 |
Ａｔｎ１のアンチセンスオリゴヌクレオチド
|
|
US20230159925A1
(en)
|
2020-03-04 |
2023-05-25 |
Nissan Chemical Corporation |
Antisense oligonucleotide of calm2
|
|
WO2021184021A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting pmp22
|
|
WO2021184020A1
(en)
|
2020-03-13 |
2021-09-16 |
Codiak Biosciences, Inc. |
Methods of treating neuroinflammation
|
|
US20230174981A1
(en)
|
2020-03-16 |
2023-06-08 |
National University Corporation Tokyo Medical And Dental University |
Heteronucleic acid containing morpholino nucleic acid
|
|
WO2021188611A1
(en)
|
2020-03-18 |
2021-09-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
|
|
EP4150092A4
(en)
|
2020-05-11 |
2024-11-06 |
Stoke Therapeutics, Inc. |
OPA1 ANTISENSE OLIGOMERS FOR THE TREATMENT OF DISEASES AND CONDITIONS
|
|
EP4166563A4
(en)
|
2020-06-15 |
2023-12-27 |
LIID Pharmaceuticals, Inc. |
Bridged nucleoside and nucleotide
|
|
WO2022076596A1
(en)
|
2020-10-06 |
2022-04-14 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting stat6
|
|
US20230263808A1
(en)
*
|
2020-10-16 |
2023-08-24 |
University Of Florida Research Foundation, Incorporated |
Therapeutic uses of glucocorticoids with anabolic effects in skeletal muscle
|
|
US11987795B2
(en)
|
2020-11-24 |
2024-05-21 |
The Broad Institute, Inc. |
Methods of modulating SLC7A11 pre-mRNA transcripts for diseases and conditions associated with expression of SLC7A11
|
|
CR20230308A
(es)
|
2020-12-11 |
2023-09-08 |
Civi Biopharma Inc |
Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
|
|
EP4237561A1
(en)
|
2020-12-23 |
2023-09-06 |
Argonaute Rna Limited |
Treatment of cardiovascular disease
|
|
CA3202832A1
(en)
|
2020-12-31 |
2022-07-07 |
Romesh R. Subramanian |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
EP4294421A2
(en)
|
2021-02-17 |
2023-12-27 |
Lonza Sales AG |
Extracellular vesicle-nlrp3 antagonist
|
|
KR20230166101A
(ko)
|
2021-04-01 |
2023-12-06 |
론자 세일즈 아게 |
세포외 소포 조성물
|
|
JPWO2022250050A1
(enExample)
|
2021-05-25 |
2022-12-01 |
|
|
|
EP4347828A1
(en)
|
2021-05-29 |
2024-04-10 |
1Globe Health Institute LLC |
Short duplex dna as a novel gene silencing technology and use thereof
|
|
EP4347829A1
(en)
|
2021-05-29 |
2024-04-10 |
1Globe Health Institute LLC |
Asymmetric short duplex dna as a novel gene silencing technology and use thereof
|
|
KR20240016342A
(ko)
|
2021-05-31 |
2024-02-06 |
레나 테라퓨틱스 인크. |
리간드-결합 핵산 복합체
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
WO2023003805A1
(en)
|
2021-07-19 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
|
|
US20240352468A1
(en)
|
2021-08-04 |
2024-10-24 |
The University Of Tokyo |
Hairpin nucleic acid composition
|
|
JPWO2023022229A1
(enExample)
|
2021-08-19 |
2023-02-23 |
|
|
|
US20240390508A1
(en)
|
2021-08-21 |
2024-11-28 |
Takeda Pharmaceutical Company Limited |
Human transferrin receptor binding peptide-drug conjugate
|
|
JP2024532476A
(ja)
*
|
2021-09-02 |
2024-09-05 |
モレキュラー アクシオム エルエルシー |
Ｎｌｒｐ３またはｎｌｒｐ１発現を調節するための組成物及び方法
|
|
US20250283076A1
(en)
|
2021-09-14 |
2025-09-11 |
Argonaute RNA Limited |
Treatment of cardiovascular disease
|
|
EP4403191A1
(en)
|
2021-09-15 |
2024-07-24 |
National University Corporation Tokyo Medical and Dental University |
Heteronucleic acid including 2'-modified nucleoside
|
|
IL311454A
(en)
|
2021-09-20 |
2024-05-01 |
Alnylam Pharmaceuticals Inc |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
|
WO2023080159A1
(ja)
|
2021-11-02 |
2023-05-11 |
レナセラピューティクス株式会社 |
リガンド結合核酸複合体
|
|
EP4430184A2
(en)
|
2021-11-11 |
2024-09-18 |
F. Hoffmann-La Roche AG |
Pharmaceutical combinations for treatment of hbv
|
|
DE102021131135A1
(de)
|
2021-11-26 |
2023-06-01 |
Zf Cv Systems Global Gmbh |
Funkkommunikationsmodul und Verfahren zum Absetzen eines Notrufs per Funkkommunikation
|
|
JP2024546993A
(ja)
|
2021-12-17 |
2024-12-26 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｒｔｅｌ１及びｆｕｂｐ１を調節するためのオリゴヌクレオチドの組み合わせ
|
|
EP4493570A2
(en)
|
2022-03-16 |
2025-01-22 |
Empirico Inc. |
Galnac compositions for improving sirna bioavailability
|
|
CA3246872A1
(en)
|
2022-03-28 |
2023-10-05 |
Empirico Inc. |
MODIFIED OLIGONUCLEOTIDES
|
|
IL316143A
(en)
|
2022-04-15 |
2024-12-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
|
|
KR20250054842A
(ko)
|
2022-07-29 |
2025-04-23 |
리제너론 파마슈티칼스 인코포레이티드 |
뇌 및 근육으로의 트랜스페린 수용체(tfr)-매개 전달을 위한 조성물 및 방법
|
|
WO2024050261A1
(en)
|
2022-08-29 |
2024-03-07 |
University Of Rochester |
Antisense oligonucleotide-based anti-fibrotic therapeutics
|
|
EP4340411A1
(en)
|
2022-09-19 |
2024-03-20 |
Cellnex Italia S.p.A |
System for monitoring the operating state of the emergency call service into tunnels
|
|
EP4596694A1
(en)
|
2022-09-29 |
2025-08-06 |
Institute Of Science Tokyo |
Nucleic acid molecule containing 5'-cyclopropylene modification
|
|
WO2024098061A2
(en)
|
2022-11-04 |
2024-05-10 |
Genkardia Inc. |
Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure
|
|
CN120693347A
(zh)
|
2022-11-04 |
2025-09-23 |
瑞泽恩制药公司 |
钙电压门控通道辅助亚基γ1(CACNG1)结合蛋白和CACNG1介导的向骨骼肌的递送
|
|
WO2024107765A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
WO2024175586A2
(en)
|
2023-02-21 |
2024-08-29 |
Vib Vzw |
Inhibitors of synaptogyrin-3 expression
|
|
WO2024175588A1
(en)
|
2023-02-21 |
2024-08-29 |
Vib Vzw |
Oligonucleotides for modulating synaptogyrin-3 expression
|
|
TW202449167A
(zh)
|
2023-04-26 |
2024-12-16 |
美商航海家醫療公司 |
用於治療肌肉萎縮性脊髓側索硬化症之組成物及方法
|